Figure 3.
Serum-vedolizumab from switch to 18 months of follow-up and median s-vedolizumab dose. S-VDZ s-vedolizumab. IQR inter quartile range. †dose at switch calculated on planned interval during the first month after switch.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.